Early Estimate of Nirsevimab Effectiveness for Prevention of Respiratory Syncytial Virus–Associated...
Early Estimate of Nirsevimab Effectiveness for Prevention of Respiratory Syncytial Virus–Associated Hospitalization Among Infants Entering Their First Respiratory Syncytial Virus Season — New Vaccine Surveillance Network, October 2023–February 2024
About this item
Full title
Author / Creator
Moline, Heidi L. , Tannis, Ayzsa , Toepfer, Ariana P. , Williams, John V. , Boom, Julie A. , Englund, Janet A. , Halasa, Natasha B. , Staat, Mary Allen , Weinberg, Geoffrey A. , Selvarangan, Rangaraj , Michaels, Marian G. , Sahni, Leila C. , Klein, Eileen J. , Stewart, Laura S. , Schlaudecker, Elizabeth P. , Szilagyi, Peter G. , Schuster, Jennifer E. , Goldstein, Leah , Musa, Samar , Piedra, Pedro A. , Zerr, Danielle M. , Betters, Kristina A. , Rohlfs, Chelsea , Albertin, Christina , Banerjee, Dithi , McKeever, Erin R. , Kalman, Casey , Clopper, Benjamin R. , McMorrow, Meredith L. , Dawood, Fatimah S. , Link-Gelles, Ruth , Payne, Amanda , Wiegand, Ryan , Correa, Ximena Aguilera , Pulido, Claudia Guevara , Grioni, Hanna , Strelitz, Bonnie , Avadhanula, Vasanthi , Munoz, Flor M. , Fregoe, Wende , Peri, Saranya , Sasidharan, Anjana , Johnson, Monika , Dauer, Klancie and New Vaccine Surveillance Network Product Effectiveness Collaborators
Publisher
United States: U.S. Government Printing Office
Journal title
Language
English
Formats
Publication information
Publisher
United States: U.S. Government Printing Office
Subjects
More information
Scope and Contents
Contents
Respiratory syncytial virus (RSV) is the leading cause of hospitalization among infants in the United States. In August 2023, CDC's Advisory Committee on Immunization Practices recommended nirsevimab, a long-acting monoclonal antibody, for infants aged <8 months to protect against RSV-associated lower respiratory tract infection during their first...
Alternative Titles
Full title
Early Estimate of Nirsevimab Effectiveness for Prevention of Respiratory Syncytial Virus–Associated Hospitalization Among Infants Entering Their First Respiratory Syncytial Virus Season — New Vaccine Surveillance Network, October 2023–February 2024
Authors, Artists and Contributors
Author / Creator
Tannis, Ayzsa
Toepfer, Ariana P.
Williams, John V.
Boom, Julie A.
Englund, Janet A.
Halasa, Natasha B.
Staat, Mary Allen
Weinberg, Geoffrey A.
Selvarangan, Rangaraj
Michaels, Marian G.
Sahni, Leila C.
Klein, Eileen J.
Stewart, Laura S.
Schlaudecker, Elizabeth P.
Szilagyi, Peter G.
Schuster, Jennifer E.
Goldstein, Leah
Musa, Samar
Piedra, Pedro A.
Zerr, Danielle M.
Betters, Kristina A.
Rohlfs, Chelsea
Albertin, Christina
Banerjee, Dithi
McKeever, Erin R.
Kalman, Casey
Clopper, Benjamin R.
McMorrow, Meredith L.
Dawood, Fatimah S.
Link-Gelles, Ruth
Payne, Amanda
Wiegand, Ryan
Correa, Ximena Aguilera
Pulido, Claudia Guevara
Grioni, Hanna
Strelitz, Bonnie
Avadhanula, Vasanthi
Munoz, Flor M.
Fregoe, Wende
Peri, Saranya
Sasidharan, Anjana
Johnson, Monika
Dauer, Klancie
New Vaccine Surveillance Network Product Effectiveness Collaborators
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10932582
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10932582
Other Identifiers
ISSN
0149-2195,1545-861X
E-ISSN
1545-861X
DOI
10.15585/mmwr.mm7309a4
